Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1;5(7):938-940.
doi: 10.34067/KID.0000000000000488.

Navigating How to Initiate Tenapanor Therapy in the Real World

Keisuke Soeda  1 , Hirotaka Komaba  1   2
Affiliations

Navigating How to Initiate Tenapanor Therapy in the Real World

Keisuke Soeda et al. Kidney360. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/KN9/A550.

References

    1. Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1–59. doi:10.1016/j.kisu.2017.04.001 - DOI - PMC - PubMed
    1. King AJ Siegel M He Y, et al. . Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):eaam6474. doi:10.1126/scitranslmed.aam6474 - DOI - PMC - PubMed
    1. Block GA Rosenbaum DP Leonsson-Zachrisson M, et al. . Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933–1942. doi:10.1681/ASN.2016080855 - DOI - PMC - PubMed
    1. Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol. 2019;30(4):641–652. doi:10.1681/ASN.2018080832 - DOI - PMC - PubMed
    1. Block GA Bleyer AJ Silva AL, et al. . Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized phase 3 trial (PHREEDOM). Kidney360. 2021;2(10):1600–1610. doi:10.34067/KID.0002002021 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources